Lipocine Inc., a biopharmaceutical company, has announced a license, development and supply agreement with SPC Korea granting exclusive rights to market TLANDO, its oral testosterone replacement therapy, in South Korea.   Under the terms of the distribution and license agreement, Lipocine will receive an upfront payment and is also eligible to receive certain regulatory and sales milestone payments, including payment upon regulatory approval of TLANDO in South Korea. Lipocine is entitled to ro...